Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Acumen Pharmaceuticals Inc

Healthcare US ABOS

2.385USD
-0.015(0.62%)

Last update at 2026-06-23T15:06:00Z

Day Range

2.352.51
LowHigh

52 Week Range

0.963.60
LowHigh

Fundamentals

  • Previous Close 2.40
  • Market Cap205.08M
  • Volume107303
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-123.77400M
  • Revenue TTM0.33M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM -104.88500M
  • Diluted EPS TTM-2.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -121.33500M -102.32900M -52.37100M -42.85600M -100.60600M
Minority interest - - - - -
Net income -121.33500M -102.32900M -52.37100M -40.47500M -181.67900M
Selling general administrative 18.95M 20.22M 18.82M 12.88M 7.28M
Selling and marketing expenses - - 0.18M - -
Gross profit -0.18400M -0.17800M -42.31800M - -
Reconciled depreciation 0.18M 0.18M 0.19M 0.17M 0.00400M
Ebit - -98.26100M -51.79000M -45.23700M 61.57M
Ebitda -123.83200M -98.08300M -51.60600M -45.06800M 61.58M
Depreciation and amortization - 0.18M 0.18M 0.17M 0.00400M
Non operating income net other - - - -0.01100M -81.10600M
Operating income -123.83200M -114.01700M -61.13800M -45.23700M 61.57M
Other operating expenses 123.83M 114.02M 61.14M 45.24M 19.58M
Interest expense 4.22M 4.07M 0.58M 2.38M 81.02M
Tax provision - - - - -
Interest income 7.45M 14.32M 8.23M 2.39M 0.08M
Net interest income 3.22M 10.25M 8.23M 2.39M 0.08M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -2.38100M 81.07M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 123.83M 114.02M 61.14M 45.24M 19.58M
Cost of revenue 0.18M 0.18M 42.32M - -
Total other income expense net 2.50M 11.69M 8.77M 2.38M -162.17900M
Discontinued operations - - - - -
Net income from continuing ops -121.33500M -102.32900M -48.74000M -42.85600M -100.60600M
Net income applicable to common shares - - - -42.85600M -100.60600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 122.83M 238.99M 310.12M 196.59M 230.33M
Intangible assets 0.03M 0.07M - - -
Earning assets - - - - -
Other current assets 4.76M 6.59M 2.87M 2.72M 4.42M
Total liab 52.40M 57.18M 43.15M 7.81M 5.15M
Total stockholder equity 70.43M 181.82M 266.97M 188.78M 225.18M
Deferred long term liab - - - - -
Other current liab 20.54M 21.83M 10.73M 6.07M 4.06M
Common stock 0.00600M 0.00600M 0.00600M 0.00400M 0.00400M
Capital stock 0.00600M 0.00600M 0.00600M 0.00400M 0.00400M
Retained earnings -446.46200M -325.12700M -222.79800M -170.42700M -127.57100M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 0.15M 0.01M
Cash 53.99M 35.63M 66.89M 130.10M 122.16M
Cash and equivalents - - - - -
Total current liabilities 30.01M 27.61M 12.97M 7.81M 5.15M
Current deferred revenue - - - - -
Net debt -22.67800M -5.92500M -35.83900M -129.99600M -122.16200M
Short term debt 8.91M 0.13M 0.87M 0.10M 0.14M
Short long term debt 8.77M - - - -
Short long term debt total 31.31M 29.70M 31.05M 0.10M 0.20M
Other stockholder equity 516.80M 506.99M 489.45M 359.95M 122.65M
Property plant equipment - - - 0.17M 0.04M
Total current assets 122.25M 178.31M 246.62M 180.33M 198.66M
Long term investments 0.00000M 59.97M 62.55M 15.84M 31.62M
Net tangible assets - - - 188.78M 225.18M
Short term investments 62.88M 135.93M 176.64M 47.50M 72.08M
Net receivables 0.62M 0.40M 0.23M 0.10M 0.10M
Long term debt 22.40M 28.45M 27.34M - -
Inventory - 0.16M 0.00010M 0.20M 0.08M
Accounts payable 0.55M 5.65M 1.38M 1.64M 1.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.08M -0.04800M 0.31M -0.75100M -0.23100M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00400M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -170.42700M -127.57100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.58M 0.38M 0.22M 0.15M 0.01M
Deferred long term asset charges - - - - -
Non current assets total 0.58M 60.69M 63.51M 16.26M 31.67M
Capital lease obligations 0.15M 0.28M 1.15M 0.10M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 134.02M 48.03M -143.28400M 39.35M -104.08000M
Change to liabilities - - - 2.56M 0.56M
Total cashflows from investing activities 133.93M 48.03M -171.67100M 39.19M -104.12000M
Net borrowings 0.00000M -0.73900M 30.00M - -
Total cash from financing activities -0.03400M 6.93M 151.75M 3.91M 200.47M
Change to operating activities - - - 3.43M -0.25900M
Net income -121.33500M -102.32900M -52.37100M -42.85600M -100.60600M
Change in cash 18.36M -31.26000M -62.98200M 7.94M 78.39M
Begin period cash flow 35.86M 67.12M 130.10M 122.16M 43.78M
End period cash flow 54.22M 35.86M 67.12M 130.10M 122.16M
Total cash from operating activities -115.53800M -86.21500M -43.06400M -35.15300M -17.96100M
Issuance of capital stock 0.00000M 7.94M 126.09M 3.79M 198.59M
Depreciation -0.75100M 0.18M 0.18M 0.17M 0.00400M
Other cashflows from investing activities - - 0.00300M - -
Dividends paid - 0.00000M 0.00000M - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -0.07300M -0.04100M 0.00000M 3.91M 170.44M
Other cashflows from financing activities - -0.23000M -0.15100M 0.12M 31.91M
Change to netincome - - - 3.06M 82.34M
Capital expenditures 0.09M 0.02M 0.02M 0.16M 0.04M
Change receivables - - - - -
Cash flows other operating - - - 1.56M 77.26M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 7.94M 78.39M
Change in working capital -5.11900M 11.65M 3.87M 3.99M 0.30M
Stock based compensation 9.85M 9.63M 6.14M 3.06M 0.92M
Other non cash items 1.81M -5.35200M -0.88800M 0.49M 81.27M
Free cash flow -115.62600M -86.23100M -43.08500M -35.31400M -18.00100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABOS
Acumen Pharmaceuticals Inc		 -0.015 0.62% 2.38 - - 538.78 2.92 24.48 -0.5955
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Acumen Pharmaceuticals Inc

1210-1220 Washington St., Newton, MA, United States, 02465

Key Executives

Name Title Year Born
Mr. Daniel J. O'Connell M.B.A. CEO, Pres & Director 1971
Mr. Matt Zuga CFO, Chief Bus. Officer & Corp. Sec. NA
Dr. Eric Siemers M.D. Chief Medical Officer 1955
Mr. Russell Barton M.S. Chief Operating Officer 1959
Mr. Derek M. Meisner Esq., J.D. Chief Legal Officer 1971
Ms. Robyn Moxon M.A. Mang. of Corp. & Clinical Communications NA
Ms. Julie Bockenstette Exec. VP & Head of HR NA
Ms. Siew Tin Gan M.S. Assistant VP & Head of Clinical Operations NA
Ms. Janice Hitchcock VP & Head of Regulatory Affairs NA
Ms. Liean Schenck M.S. VP & Head of CMC NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.